Can a Two-Drug cocktail reverse liver scarring? early trial hints at possibility
NCT ID NCT05506488
First seen Feb 19, 2026 · Last updated Jun 23, 2026 · Updated 18 times
Summary
This study tested whether a combination of two drugs, dasatinib and quercetin, can reduce liver scarring in people with non-alcoholic fatty liver disease (NAFLD) and fibrosis. Thirty adults with biopsy-confirmed liver scarring took either the drug combo or a placebo in cycles over 21 weeks. The goal was to see if the treatment improved fibrosis by at least one point on a standard scoring system without worsening other liver damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Amsterdam UMC location AMC
Amsterdam, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dasatinib and quercetin
What this could lead to
If it works, this could point toward a treatment that reduces liver scarring in people with fatty liver disease, potentially preventing progression to cirrhosis.
What could go wrong
This is a very small, early-phase study with only 30 participants. The results may not apply to everyone, and the treatment could cause side effects like nausea or low blood counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.